December 14, 2022
Obsidian Therapeutics to Present at RBC Capital Markets Healthcare Private Company Conference
CAMBRIDGE, Mass., December 14, 2022 – Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that management will attend the RBC Capital Markets Healthcare Private Company Conference. The event will be hosted virtually, from December 14-15, 2022.
Jan ter Meulen, M.D., Ph.D., Chief Scientific Officer of Obsidian, will be presenting and participating in a fireside chat on December 14, at 10:40 a.m. E.T. Obsidian will also take part in 1×1 investor meetings during the event.
Obsidian’s lead investigational cytoTIL15 program, OBX-115, is a novel engineered tumor-infiltrating lymphocyte (TIL) therapy armed with regulated membrane-bound IL15 that has the potential to become a meaningful therapeutic option for patients suffering from metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process. OBX-115 preclinical data have demonstrated enhanced TIL persistence, potency and improved tumor control compared to unengineered TILs plus IL2. OBX-115 also has the potential benefit to patients by removing the need for concomitant IL2 therapy, which is both costly and typically poorly tolerated, limiting the potential eligible patient population for TIL therapy. The Phase I FIH clinical trial for OBX-115 is currently recruiting patients. Information regarding the clinical trial is available at clinicaltrials.gov: NCT05470283.
About Obsidian Therapeutics
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Obsidian Therapeutics Media Contact:
Erica Fiorini, Ph.D., or Liz Philips, Russo Partners, LLC
+1 (914) 310-8172